News by Subject Biology

Results of a compassionate-use study released in STEM CELLS Translational Medicine show promising results for treating muscular dystrophies with mesenchymal stem cells (MSCs) derived from Wharton's jelly (WJ), a substance found in the umbilical cord.

Cell-free DNA (cfDNA) shed into the blood was discovered in the late 1940s but with rapid advances in genomics and computational analytics in just the past few years, researchers at Georgetown Lombardi Comprehensive Cancer Center now believe that studying tags, or modifications to this type of DNA, may lead to a better understanding of how to assess, and possibly modulate, treatment approaches for cancer and other diseases. Their perspective, drawn from a review of studies to date, appears July 27 in Frontiers in Genetics.

How early is the course of COVID-19, mild or severe, determined? In Cell, researchers examined nasal cells sampled from patients at the time of diagnosis, looking for differences between those who developed severe disease and those who experienced a mild illness. Cells from patients who developed severe COVID-19 exhibited a more muted antiviral response. If the early stages of infection can determine disease severity, it opens a path for scientists to develop early therapeutic interventions.

The body's first encounter with the coronavirus happens in the nose and throat. New work in Cell suggests that responses in this early battleground help determine who will develop severe COVID-19 and who will have only mild or no illness. It used single-cell RNA sequencing of all the cell types recovered from nasal swabs of people with and without COVID-19.

After gaining world attention by 'unboiling' egg protein, Flinders University scientists have now used an Australian-made novel thin film microfluidic device to manipulate Beta-lactoglobulin (β-lactoglobulin), the major whey protein in cow's, sheep's and other mammals. In the latest application, published in Molecules, College of Science and Engineering experts have combined the capabilities of the VFD with a new form of biosensor called TPE-MI, which is an aggregation-induced emission luminogen (AIEgen).

EPFL researchers have characterized a mechanism that allows bacteria to direct their movement in response to the mechanical properties of the surfaces the microbes move on -- a finding that could help fight certain pathogens.

Research in mice, published today in Science Immunology by researchers at the Babraham Institute, UK and VIB-KU Leuven, Belgium, provides two solutions with potential to overcome a key clinical limitation of immune cell therapies.